Announcements Trials
Browse Landscape

Status

Unknown 4Completed 4Terminated 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 3Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Sleep Apnea, Obstructive 1Skin Diseases 1Polycythemia Vera 1Neoplasms by Site 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms 1Breast Diseases 1Brain Neoplasms 1Body Weight Changes 1Anorexia 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of the Prostate 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Watchful Waiting × Clear all
NCT04791215 2024-10-26

Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

Columbia University

Terminated
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04016935 2022-05-17

EndoPredict® Extended Endocrine Trial (EXET)

Myriad Genetic Laboratories, Inc.

Terminated
855 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡